Patents Issued in November 5, 2020
  • Publication number: 20200345685
    Abstract: A medicinal cannabis mixture has cannabis oil and one or more transdermal agents that increase permeability of skin to passage of cannabis. In a process of administering the mixture the solution is applied to a subject's skin over an artery.
    Type: Application
    Filed: May 2, 2019
    Publication date: November 5, 2020
    Inventor: Christopher Ayo Otiko
  • Publication number: 20200345686
    Abstract: Described herein are compositions for treating dermatological conditions, such as skin conditions, as well as neuropathological conditions and disorders, particularly those requiring relief from pain and physical discomfort. The compositions as described may be topically or transdermally administered. In some aspects, the compositions and products comprise a pharmaceutically acceptable amount of at least one analgesic component and a cannabis component and are useful to relieve acute or chronic pain, inflammation, and the like, following application.
    Type: Application
    Filed: April 28, 2020
    Publication date: November 5, 2020
    Applicant: VCP IP HOLDINGS, LLC, LIMITED LIABILITY COMPANY DELAWARE
    Inventors: ANDREA BAILLO, ALEXANDRA DePALMA
  • Publication number: 20200345687
    Abstract: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
    Type: Application
    Filed: March 9, 2018
    Publication date: November 5, 2020
    Inventor: Lisa A. Conte
  • Publication number: 20200345688
    Abstract: A pharmaceutical composition for preventing and treating liver diseases, includes cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Application
    Filed: January 29, 2020
    Publication date: November 5, 2020
    Inventor: Jin Woo CHOI
  • Publication number: 20200345689
    Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-001 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-001 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing ?-rays, ?-rays, ?-rays, neutron radiation, or a combination thereof.
    Type: Application
    Filed: January 8, 2019
    Publication date: November 5, 2020
    Applicant: EpicentRx, Inc.
    Inventors: Bryan T. ORONSKY, Amold ORONSKY
  • Publication number: 20200345690
    Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OO1 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OO1 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing ?-rays, ?-rays, ?-rays, neutron radiation, or a combination thereof.
    Type: Application
    Filed: January 8, 2019
    Publication date: November 5, 2020
    Applicant: EpicentRx, Inc.
    Inventors: Bryan T. ORONSKY, Amold ORONSKY, Tony R. REID
  • Publication number: 20200345691
    Abstract: Compositions comprising an AhR agonist compound, such as indigo and/or an indigo derivative, such as indirubin and isatin, are described. Methods of treatment, including the treatment of ulcerative colitis, by administering the compositions are described. In an embodiment, compositions in the form of a solid amorphous dispersion of the AhR agonist are described.
    Type: Application
    Filed: June 3, 2020
    Publication date: November 5, 2020
    Inventors: Julie Patricia Saiki, Matthew Davidson, Johan Oscar Lennart Andreasson, Michael David Favero, Matthew Benjamin Greene
  • Publication number: 20200345692
    Abstract: Disclosed herein are compositions and methods for treating cancer. More particularly, the present disclosure relates to compositions and methods for treating cancer including prostate cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, sarcoma breast cancer, and gastrointestinal stromal tumor. The present disclosure also relates to methods for identifying subjects having drug resistant prostate cancer and drug resistant renal cell carcinoma.
    Type: Application
    Filed: January 18, 2019
    Publication date: November 5, 2020
    Inventor: Roberto Pili
  • Publication number: 20200345693
    Abstract: Disclosed herein inter alia are compositions and methods for treating cancer using thioindirubin derivatives.
    Type: Application
    Filed: August 30, 2018
    Publication date: November 5, 2020
    Inventors: Sangkil Nam, David Horne, Ravi Salgia, Alexios Leandros Skaltsounis, Nicolas Gaboriaud-Kolar, Panagiotis Gerolymatos, Nikolaos Lougiakis
  • Publication number: 20200345694
    Abstract: The present disclosure relates to an antiaging composition containing cytochalasin D or SAG, and a method for screening an antiaging substance, and provides a new antiaging substance and a new method for discovering a new antiaging substance. Thus, it is possible to greatly contribute to the development of beauty industries and to meeting demands related with beauty and antiaging, if the present disclosure is effectively used.
    Type: Application
    Filed: July 24, 2018
    Publication date: November 5, 2020
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Hyun Jung CHOI, Hyoung June KIM, Ji Yong JUNG, Tae Ryong LEE
  • Publication number: 20200345695
    Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.
    Type: Application
    Filed: December 2, 2019
    Publication date: November 5, 2020
    Inventor: Kazuhiro KIMURA
  • Publication number: 20200345696
    Abstract: Provided are topical analgesic compositions and methods of preparing topical analgesic compositions comprising a stable nano-encapsulating matrix film. The topical analgesic compositions and methods of preparing topical analgesic compositions may be suited for roll-on applicators. Topical analgesic compositions may include 12 to 16 wt. % menthol; 4 to 8 wt. % camphor; 2 to 15 wt. % film-forming polymer; and 50 to 70 wt. % solvent. To be used in a roll-on applicator, the topical analgesic composition has a viscosity from 800 to 1400 centipoise.
    Type: Application
    Filed: April 23, 2020
    Publication date: November 5, 2020
    Inventors: Debanjan DAS, Emanuel VIZZOTTI, Thomas DANN, Renee NELSON, Courtney C. HAYNES, Soundarya VAITHIANATHAN, Reginald BRADLEY, Reinhard WALTER, Gerard MEISEL
  • Publication number: 20200345697
    Abstract: The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort.
    Type: Application
    Filed: September 5, 2019
    Publication date: November 5, 2020
    Inventors: DAVID FREDERICK WOODWARD, WEIZHEN WANG
  • Publication number: 20200345698
    Abstract: The present disclosure related to methods of treating pruritus in a subject by topically administering detomidine, or a pharmaceutically acceptable salt thereof, to the subject.
    Type: Application
    Filed: May 1, 2020
    Publication date: November 5, 2020
    Inventors: Yael Rosen, David Dangoor, Richard Fisher
  • Publication number: 20200345699
    Abstract: The present disclosure provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject. The disclosure also provides pharmaceutical compositions comprising these compounds, processes for preparing them, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject using these compounds. The present disclosure also provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of a coronavirus, treating coronavirus symptoms or delaying the onset of coronavirus symptoms in a subject.
    Type: Application
    Filed: April 15, 2020
    Publication date: November 5, 2020
    Inventors: Aesop Cho, John O. Link, Jie Xu
  • Publication number: 20200345700
    Abstract: A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.
    Type: Application
    Filed: January 24, 2018
    Publication date: November 5, 2020
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Lingyun WU, Li ZHANG, Lele ZHAO, Jianjun SUN, Zhaoguo CHEN, Jian Ll, Shuhui CHEN
  • Publication number: 20200345701
    Abstract: The present invention relates to a beta-lactam antibiotic for use in a method of treating a bacterial infection in a subject in need thereof wherein said bacterial infection is caused by a bacterial species characterized by using the mevalonate synthetic pathway, wherein said subject is further treated, before or simultaneously to said beta-lactam antibiotic, with a statin, wherein said statin is for use in reducing, mitigating or reversing resistance to said beta-lactam antibiotic in resistant bacterial populations of said bacterial species.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Inventors: Daniel LÓPEZ SERRANO, Gudrun KOCH
  • Publication number: 20200345702
    Abstract: Methods for removing excess free ?-globin in erythroid cells and treating a thalassemia using an agent that activates Unc-51 Like autophagy activating Kinase (ULK) are described.
    Type: Application
    Filed: October 26, 2018
    Publication date: November 5, 2020
    Inventors: Mitchell J. Weiss, Mondira Kundu, Christophe Lechauve
  • Publication number: 20200345703
    Abstract: A method of preventing or treating an immunological or inflammatory disease or disorder comprising administering a composition including a combination of rapamycin and metformin, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1; 10:1 to about 4:1; 5:1 to about 3:1; or about 5:1 to about 4:1. The composition may be formulated for oral administration, topical administration, parenteral administration, etc.
    Type: Application
    Filed: July 16, 2020
    Publication date: November 5, 2020
    Inventor: Jeffrey M. Melin
  • Publication number: 20200345704
    Abstract: The present invention provides methods of treating hematological disorders and solid malignant tumors, using substituted indazole compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and BCL-2 kinases.
    Type: Application
    Filed: July 21, 2020
    Publication date: November 5, 2020
    Inventor: Robert Booher
  • Publication number: 20200345705
    Abstract: Described herein is (4R,7,S)-2-(3-(4-chlorophenyl)ureido)-9-methyl-5,6,7,8-tetrahydro-4H-4,7-epiminocyclohepta[b]thiophene-3-carboxamide mesylate, including crystalline forms and solvates thereof.
    Type: Application
    Filed: August 31, 2018
    Publication date: November 5, 2020
    Applicant: University of Washington
    Inventors: Graham Johnson, Edwin Aret, Alexei Tchesnokov
  • Publication number: 20200345706
    Abstract: The invention relates to amide-derivatives of 2-hydroxy-2-methyl-4-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-butanoic acid for use in a treatment for preventing or suppressing symptoms mediated by enhanced mPGES-1 expression or activity. In particular the invention relates the use of these compounds for treating diseases and conditions in which the inhibition of the enzyme mPGES-1 activity and/or expression would be beneficial such as inflammatory diseases, nociceptive pain, auto-immune diseases, breathing disorders, fever, cancer, inflammation related anorexia, Alzheimer's disease and cardiovascular disease.
    Type: Application
    Filed: November 22, 2018
    Publication date: November 5, 2020
    Applicant: Khondrion IP B.V.
    Inventors: Johannes Albertus Maria Smeitink, Julien David Beyrath
  • Publication number: 20200345707
    Abstract: Many Gram-negative pathogens assemble adhesive pili structures on their surfaces that allow them to colonize host tissues and cause disease. The present invention relates to novel compounds that disrupt the intramolecular interactions of the pilus subunits thereby reducing pilus assembly.
    Type: Application
    Filed: January 27, 2020
    Publication date: November 5, 2020
    Inventors: Scott HULTGREN, Natalie OMATTAGE, Fredrik ALMQVIST, Jerome PINKNER, Karen DODSON, Peng YUAN
  • Publication number: 20200345708
    Abstract: The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.
    Type: Application
    Filed: April 13, 2020
    Publication date: November 5, 2020
    Applicant: Ferring International Center S.A.
    Inventors: Bong Gil NAM, Byeung Jun LEE, Shunji JIN
  • Publication number: 20200345709
    Abstract: The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.
    Type: Application
    Filed: March 23, 2018
    Publication date: November 5, 2020
    Inventor: Takeshi JIMBO
  • Publication number: 20200345710
    Abstract: Compositions and methods for treating epilepsy and epileptic syndromes are described herein. The compositions and methods include therapeutically effective amounts of one or more dimebolins, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: February 7, 2020
    Publication date: November 5, 2020
    Inventors: Spyros Deftereos, Andreas Persidis
  • Publication number: 20200345711
    Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
    Type: Application
    Filed: February 10, 2020
    Publication date: November 5, 2020
    Inventors: James Densmore Copp, Ann W. Newman, Anne Luong
  • Publication number: 20200345712
    Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.
    Type: Application
    Filed: May 1, 2020
    Publication date: November 5, 2020
    Inventors: Nicolas Nassar, William Seibel, Anjelika Gasilina, Jose Cancelas
  • Publication number: 20200345713
    Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.
    Type: Application
    Filed: December 27, 2018
    Publication date: November 5, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Hisashi Kawata, Noriko Kawabata, Naveed Shams
  • Publication number: 20200345714
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Application
    Filed: July 13, 2020
    Publication date: November 5, 2020
    Applicants: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
  • Publication number: 20200345715
    Abstract: Ligands of the mu, kappa, and delta opioid receptors and methods of using them are disclosed. In particular, the invention relates to the discovery of new opioid receptor ligands based on molecular dynamics simulations of conformational states of the ? opioid receptor and the use of the identified opioid receptor ligands as analgesics, anti-diarrheal agents, and overdose reversal agents.
    Type: Application
    Filed: November 14, 2018
    Publication date: November 5, 2020
    Inventors: Evan N. Feinberg, Vijay S. Pande, Susruta Majumdar, Gavril Pasternak
  • Publication number: 20200345716
    Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.
    Type: Application
    Filed: July 21, 2020
    Publication date: November 5, 2020
    Inventors: Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
  • Publication number: 20200345717
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 18, 2019
    Publication date: November 5, 2020
    Applicant: AbbVie Inc.
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Publication number: 20200345718
    Abstract: The instant application relates to morphinan derivatives of Formula I with sustained effectiveness in treating drug toxicity and overdose:
    Type: Application
    Filed: February 7, 2020
    Publication date: November 5, 2020
    Inventors: Bernard Silverman, Fen-Ni Fu, Chengyun Guo
  • Publication number: 20200345719
    Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
    Type: Application
    Filed: May 22, 2020
    Publication date: November 5, 2020
    Inventors: Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
  • Publication number: 20200345720
    Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
    Type: Application
    Filed: March 18, 2020
    Publication date: November 5, 2020
    Applicant: Fresenius Kabi Deutschland GmbH
    Inventors: Alain CUINE, Didier HOARAU, Pauline ROMAIN
  • Publication number: 20200345721
    Abstract: The present disclosure relates to devices for deterring drug abuse and methods thereof. More particularly, the disclosure relates to devices for deterring drug abuse by using physical deterrents and/or deterrent substances, including a mechanism that releases a deterrent substance when improper access of the drug is attempted, and methods thereof.
    Type: Application
    Filed: April 28, 2020
    Publication date: November 5, 2020
    Inventor: Matthew Iorio
  • Publication number: 20200345722
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 5, 2020
    Inventors: Jane HIRSH, Alison FLEMING, Roman RARIY, Alexander KLIBANOV
  • Publication number: 20200345723
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 5, 2020
    Inventors: Roman V. RARIY, Alison B. FLEMING, Jane HIRSH, Alexander M. KLIBANOV
  • Publication number: 20200345724
    Abstract: The present invention is directed to a depot composition for sustained release delivery of buprenorphine with enhanced stability and bioavailability. The composition is an injectable, low viscosity liquid and can form a depot in situ capable of delivering therapeutic level of buprenorphine over a period of time from one week to 3 months.
    Type: Application
    Filed: January 22, 2018
    Publication date: November 5, 2020
    Applicant: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua LI, MingHsin LI, Chen-Chang LEE, Chia-Ying YANG, Chih-Ying LIN
  • Publication number: 20200345725
    Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).
    Type: Application
    Filed: January 10, 2020
    Publication date: November 5, 2020
    Inventors: Michael Cicirelli, Neil S. Cutshall, Gregory A. Demopulos, George A. Gaitanaris, Marc A. Gavin, Alexander Gragerov, Thomas L. Little, Rene Onrust
  • Publication number: 20200345726
    Abstract: The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds.
    Type: Application
    Filed: January 22, 2019
    Publication date: November 5, 2020
    Applicant: Purdue Pharma L.P.
    Inventors: Stephen C. HARRIS, Ram P. KAPIL, Donald J. KYLE, Garth WHITESIDE
  • Publication number: 20200345727
    Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
    Type: Application
    Filed: November 2, 2018
    Publication date: November 5, 2020
    Inventors: Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Marina Pliushchev, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Ramzi Farah Sweis, Michael J. Dart, John T. Randolph, Kathleen J. Murauski
  • Publication number: 20200345728
    Abstract: The present invention relates to a composition for preventing or treating atherosclerosis in a subject, comprising a zinc salt and cyclo-Hispro and a method of preventing or treating atherosclerosis using thereof.
    Type: Application
    Filed: April 30, 2019
    Publication date: November 5, 2020
    Applicants: NovMetaPharma Co., Ltd., The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Moon Ki Song, Mysore S. Veena, David Scott Bischoff, Dean Takao Yamaguchi
  • Publication number: 20200345729
    Abstract: Provided are a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 22, 2018
    Publication date: November 5, 2020
    Applicant: Sumitomo Dainippon Pharma Co., Ltd.
    Inventors: Yohei IKUMA, Kengo TOJO, Ryo FUKAZAWA, Shuji MASUMOTO
  • Publication number: 20200345730
    Abstract: Disclosed herein are pharmaceutical compositions, devices, their combinations, and their uses thereof for example in treating or preventing headaches.
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Inventors: John KOLLINS, Fumiyoshi IWASHIMA, Detlef ALBRECHT, Robert David SCHULTZ
  • Publication number: 20200345731
    Abstract: Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.
    Type: Application
    Filed: April 30, 2019
    Publication date: November 5, 2020
    Inventors: Peter Henry Schafer, Robert Plenge, Mary Adams, Lisa Beebe, Gilles Buchwalter, Tiffany Carr, Te-chen Tzeng
  • Publication number: 20200345732
    Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: July 21, 2020
    Publication date: November 5, 2020
    Inventors: Atwood Kim CHEUNG, Donovan Noel CHIN, Natalie DALES, Aleem FAZAL, Timothy Brian HURLEY, John KERRIGAN, Gary O'BRIEN, Lei SHU, Robert SUN, Moo Je SUNG
  • Publication number: 20200345733
    Abstract: The present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans.
    Type: Application
    Filed: July 16, 2020
    Publication date: November 5, 2020
    Inventors: Jens Marcel Van Roey, Marie-Pierre T.M.M.G. De Bethune, Paul Stoffels
  • Publication number: 20200345734
    Abstract: Described herein are methods and pharmaceutical formulations for treating ocular conditions.
    Type: Application
    Filed: April 17, 2020
    Publication date: November 5, 2020
    Inventors: Douglas Michael ACKERMANN, James LOUDIN, Kenneth J. MANDELL